S

Senseonics Holdings Inc
AMEX:SENS

Watchlist Manager
Senseonics Holdings Inc
AMEX:SENS
Watchlist
Price: 0.316 USD -2.08% Market Closed
Market Cap: 187.3m USD
Have any thoughts about
Senseonics Holdings Inc?
Write Note

Senseonics Holdings Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Senseonics Holdings Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
S
Senseonics Holdings Inc
AMEX:SENS
Accrued Liabilities
$12.7m
CAGR 3-Years
-3%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Accrued Liabilities
$2.3B
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
7%
Stryker Corp
NYSE:SYK
Accrued Liabilities
$3.5B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
3%
Abbott Laboratories
NYSE:ABT
Accrued Liabilities
$6.5B
CAGR 3-Years
-1%
CAGR 5-Years
4%
CAGR 10-Years
6%
Intuitive Surgical Inc
NASDAQ:ISRG
Accrued Liabilities
$867.5m
CAGR 3-Years
21%
CAGR 5-Years
13%
CAGR 10-Years
15%
No Stocks Found

Senseonics Holdings Inc
Glance View

Market Cap
187.3m USD
Industry
Health Care

Senseonics Holdings, Inc. engages in the design, development, and commercialization of an implantable continuous glucose monitoring system for people with diabetes. The company is headquartered in Germantown, Maryland and currently employs 121 full-time employees. The company went IPO on 2015-03-04. The firm is focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community. Its Eversense, Eversense XL, and Eversense E3 continuous glucose monitoring (CGM) systems are designed to continually measure glucose levels in people with diabetes via an under-the-skin sensor, a removable and rechargeable smart transmitter, and a mobile application for real-time diabetes monitoring and management for a period of up to six months. The company is also developing its Gemini product variation to allow for a two-in-one glucose monitoring system combining the functionality of CGM and Flash Glucose Monitoring (FGM), in an implantable sensor that may be utilized with a smart transmitter to get continuous glucose readings and alerts or be utilized through a swipe over the sensor with a smart phone to get on-demand glucose readings without a smart transmitter.

SENS Intrinsic Value
0.139 USD
Overvaluation 56%
Intrinsic Value
Price
S

See Also

What is Senseonics Holdings Inc's Accrued Liabilities?
Accrued Liabilities
12.7m USD

Based on the financial report for Sep 30, 2024, Senseonics Holdings Inc's Accrued Liabilities amounts to 12.7m USD.

What is Senseonics Holdings Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
-7%

Over the last year, the Accrued Liabilities growth was -13%. The average annual Accrued Liabilities growth rates for Senseonics Holdings Inc have been -3% over the past three years , -7% over the past five years .

Back to Top